赛象科技(002337) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥172,584,071.32, a decrease of 14.86% compared to ¥202,704,883.19 in the same period last year[4] - Net profit attributable to shareholders was ¥5,731,388.40, down 80.14% from ¥28,857,024.84 year-on-year[4] - Basic earnings per share decreased by 80.00% to ¥0.01 from ¥0.05 in the same period last year[4] - Operating profit for Q1 2024 was CNY 4,582,282.26, down 86.06% from CNY 33,051,159.81 in the same period last year[19] - Net profit for Q1 2024 was CNY 5,034,917.65, a decline of 81.91% compared to CNY 27,848,018.98 in Q1 2023[19] - Total operating revenue for Q1 2024 was CNY 172,584,464.40, a decrease of 14.85% compared to CNY 202,741,641.03 in Q1 2023[18] Cash Flow - The net cash flow from operating activities was -¥27,179,973.29, a decline of 153.94% compared to ¥50,386,195.35 in the previous year[4] - The total cash inflow from operating activities was 191,816,933.93, down from 248,292,252.12, indicating a decline in cash generation from core operations[22] - Cash inflow from investment activities totaled 437,215,291.08, up from 402,167,222.51, reflecting an increase in investment recovery[22] - The net cash flow from investment activities was -133,523,855.52, a sharp decline compared to 45,618,912.41 in the previous period, suggesting increased investment expenditures[22] - The net cash flow from financing activities was -94,568.67, worsening from -12,570,444.97 in the previous period, highlighting challenges in financing[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,926,481,101.19, a slight decrease of 0.59% from ¥1,937,956,524.68 at the end of the previous year[4] - The company’s total liabilities decreased from CNY 1,937,956,524.68 to CNY 1,926,481,101.19, suggesting improved financial management[15] - Total liabilities decreased to CNY 610,325,142.16 from CNY 628,436,388.39, a reduction of 2.77%[19] - The total current liabilities decreased from CNY 267,869,156.25 to CNY 242,286,304.97, reflecting a reduction of approximately 9.6%[16] - The company’s cash and cash equivalents decreased to CNY 380,592,840.99 from CNY 542,746,364.36, representing a decline of approximately 30%[15] Research and Development - The company reported a significant increase in research and development expenses, which rose by 66.02% to ¥14,744,306.21 from ¥8,880,876.28 year-on-year[8] - Research and development expenses increased to CNY 14,744,306.21, up 66.67% from CNY 8,880,876.28 in the previous year[19] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 64,838[10] - The company’s weighted average return on equity decreased to 0.46% from 2.43% in the previous year[4] Governance and Compliance - The company held a board meeting on March 25, 2024, to approve amendments to the company’s articles of association, reflecting ongoing governance improvements[13] - The company has not yet audited the first quarter report, which may affect the reliability of the financial data presented[24] Tax and Subsidies - The company received government subsidies amounting to ¥705,082.80 during the reporting period[5] - The company reported a significant increase in tax expenses, totaling CNY 660,517.04 compared to CNY 222,955.58 in the previous year[19] - The company received 3,646,868.76 in tax refunds, up from 3,106,424.77, indicating improved tax recovery efforts[22] Investments - The company invested CNY 3,000,000 in Yuanshan Medical, acquiring a 1.4285% stake, as part of a larger investment round led by Haitai Haihe Fund[12]